#USA #San Francisco #Bridge to Life #Liver Transplantation #Hope

Unveiling the Future of Liver Preservation at WTC 2025

Bridge to Life™ Ltd., a global frontrunner in organ preservation and perfusion technology, recently presented pivotal data on its hypothermic oxygenated perfusion (HOPE) technique during the World Transplant Congress (WTC) 2025 in San Francisco. This prestigious event, hosted from August 2 to 6, serves as a collaborative platform for the American Society of Transplantation (AST), the American Society of Transplant Surgeons (ASTS), and The Transplantation Society (TTS), showcasing advancements in transplantation science.

Key Findings from the Bridge to HOPE Trial

One of the highlights of the Congress was the presentation of a 12-month follow-up analysis of the Bridge to HOPE trial, which emphasizes not only clinical improvements in liver transplantation but also its economic implications. The company’s findings underline the effectiveness of HOPE in enhancing graft viability and thereby reducing the incidence of complications post-transplant.

The data was showcased through multiple presentations, notably in a plenary session where Dr. Chase J. Wehrle from Cleveland Clinic discussed the differences between hypothermic and normothermic machine perfusion. The session provided insights into a comparative analysis linking trial outcomes to real-world results across institutions, highlighting the significant impact of this technology on patient care and hospital resource management.

Presentations Overview

The WTC 2025 agenda prominently featured several poster presentations that detailed the advantages of HOPE over traditional methods. Key topics included:

• - Impact on Ischemia-Reperfusion Injury – A stratified analysis based on donor age presented by Dr. Marco Maria Pascale.
• - Mitochondrial Function Analysis – A comparison study of human livers subjected to both hypothermic and normothermic machine perfusion by Dr. Omer Faruk Karakaya.
• - Economic Assessment – A critical evaluation of the cost-effectiveness of HOPE in liver transplants, highlighted by Dr. David Axelrod.

Moreover, special sessions showcased late-breaking oral abstracts including innovative approaches to assess the viability of split liver grafts and examine immunomodulation through HOPE. These presentations underscored the ongoing research and development efforts aimed at refining transplant methodologies for better outcomes.

Symposium on HOPE

In addition to the presentations, Bridge to Life™ sponsored a symposium titled “HOPE: From Science to Clinical Impact.” Scheduled for August 4, this session aimed to bridge the gap between experimental findings and practical applications in clinical settings. Distinguished speakers included Dr. David Axelrod and Dr. Andrea Schlegel, who have been instrumental in the exploration and implementation of these cutting-edge technologies.

The Future of Transplantation

Bridge to Life™ continues to be a leader in the organ preservation market, known for products like Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. With a commitment to innovation and quality, the company collaborates with leading transplant centers and organ procurement organizations worldwide, driving forward the future of transplantation.

As the medical community looks toward new horizons in transplant science, the findings presented at WTC 2025 mark a significant step forward in liver transplantation techniques, promising to enhance patient outcomes and expand the possibilities for organ preservation.

Through the integration of advanced preservation technologies such as HOPE, the path to more effective and economical liver transplantation becomes clearer, offering hope to patients and medical professionals alike.